Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia  by Blunt, Matthew D. & Steele, Andrew J.
Leukemia Research Reports 4 (2015) 60–63Contents lists available at ScienceDirectLeukemia Research Reportshttp://d
2213-04
n Corr
E-mjournal homepage: www.elsevier.com/locate/lrrPharmacological targeting of PI3K isoforms as a therapeutic strategy
in chronic lymphocytic leukaemia
Matthew D. Blunt, Andrew J. Steele n
Cancer Sciences Unit, Faculty of Medicine, University of Southampton, SO16 6YD, United Kingdoma r t i c l e i n f o
Article history:
Received 10 August 2015
Accepted 11 September 2015
Available online 18 September 2015
Keywords:
CLL
PI3K
Idelalisib
Duvelisibx.doi.org/10.1016/j.lrr.2015.09.001
89/& 2015 The Authors. Published by Elsevier
esponding author.
ail address: A.Steele@soton.ac.uk (A.J. Steele).a b s t r a c t
PI3Kδ inhibitors such as idelalisib are providing improved therapeutic options for the treatment of
chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K
isoform can be compensated by the other PI3K isoforms, therefore PI3K inhibitors which target multiple
PI3K isoforms may provide greater efﬁcacy. The development of compounds targeting multiple PI3K
isoforms (α, β, δ, and γ) in CLL cells, in vitro, resulted in sustained inhibition of BCR signalling but with
enhanced cytotoxicity and the potential for improve clinical responses. This review summarises the
progress of PI3K inhibitor development and describes the rationale and potential for targeting multiple
PI3K isoforms.
& 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
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B cell receptor (BCR) activation and subsequent downstream
signalling is pivotal for maintenance and proliferation of chronic
lymphocytic leukaemia (CLL) leading to tumour progression [1].
Therefore targeting the BCR and associated pathways is attractive
for CLL and other BCR driven B cell malignancies. These BCR sig-
nals are mediated via a series of key kinases including SYK, BTK
and PI3K, and inhibitors such as entospletinib (SYK inhibitor),
ibrutinib (BTK inhibitor) and idelalisib (PI3Kδ inhibitor) are
showing clinical efﬁcacy, and are likely to replace standard che-
motherapy regimens for the treatment of CLL. So far, with limitedLtd. This is an open access article ufollow up, ibrutinib and idelalisib have shown clear efﬁcacy in
suppressing tumour progression but have not been curative. A
minority of treated patients who go on to develop resistance to
ibrutinib have extremely poor outcomes with a median survival of
3.1 months after discontinuation [2]. However once resistance to
ibrutinib occurs, PI3K inhibitors may still be therapeutically ef-
fective [3]. This review will therefore focus on PI3K inhibitors in
CLL.
PI3K, via phosphorylation of the inositol lipid phosphatidyli-
nositol 4,5-bisphosphate (PI(4,5)P2), forms the second messenger
molecule phosphatidylinositol (3,4,5)-trisphosphate (PI(3,4,5)P3)
which recruits and activates pleckstrin homology domain con-
taining proteins, leading to downstream signalling events crucial
for proliferation, survival and migration. Class I PI3K enzymes
consist of four distinct catalytic isoforms, PI3Kα, PI3Kβ, PI3Kδ and
PI3Kγ. The PI3Kδ and PI3Kγ isoforms are expressed predominantlynder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tously expressed [4].
PI3K becomes activated upon ligation of a number of chemo-
kine and cytokine receptors expressed by CLL cells and following
BCR ligation [5,6]. PI3K mediated signalling is known to be con-
stitutively activated in CLL [6] and patients with more progressive
disease [IGHV unmutated (U-CLL)] show signiﬁcantly greater PI3K
expression compared to less progressive disease [IGHV mutated
(M-CLL)] [7].2. Pharmacological inhibition of PI3Kδ in CLL
The crucial role of PI3Kδ in normal B cell biology was identiﬁed
using genetic and pharmacological studies [4] and its haemato-
poietic restricted expression has made it an attractive target for
therapeutic intervention in haematological malignancies (Fig. 1A).
Idelalisib preferentially inhibits PI3Kδ and has recently gained
approval for the treatment of relapsed/refractory CLL. It has been
evaluated in a phase I clinical trial in 54 CLL patients with re-
lapsed/refractory disease; nodal shrinkage and overall survival
were obtained in 81% and 72% patients respectively [8]. In a phase
III clinical trial, idelalisib combined with the anti-CD20 antibody
rituximab signiﬁcantly improved progression free survival (81%)
and overall survival (91%) in relapsed CLL patients (n¼220) com-
pared to placebo plus rituximab [9]. Commonly observed adverse
events in patients taking idelalisib included pneumonia, rash and
diarrhoea [8], however idelalisib and rituximab demonstrated an
acceptable safety proﬁle with no signiﬁcant increase overall in
adverse events compared to placebo plus rituximab [9].
Idelalisib demonstrates a dual mechanism of action by in-
hibiting pro-survival signalling pathways [6], and, like other kinase
inhibitors, leads to re-localisation of tumour cells by blocking in-
gress into and promoting egress out of the lymph node into the
blood. Release from the protective lymph environment into blood
renders CLL cells more susceptible to apoptosis. PI3Kδ is expressed
by all leucocytes including T cells, raising the possibility that the
therapeutic effect of idelalisib may, at least in part, be due to ef-
fects on the surrounding immune cells in addition to direct effects
on CLL cells [10]. Intriguingly, IL-4 protects against idelalisib in-
duced apoptosis in vitro [6], indicating that microenvironmental
inﬂuences may protect CLL cells against PI3K inhibitors and thatFig. 1. Schematic representation of the PI3K/mTOR signalling pathway with pharmacolog
by receptor ligation induces re-localisation and activation of AKT (amongst other protei
survival and proliferation. PI3K inhibitors in pre-clinical development, clinical trials or
which phosphorylates S6 kinase and 4E-BP1 (eukaryotic translation initiation factor 4E-b
which phosphorylates and thus enhances the activation of AKT. (B) S6 kinase is activated
kinase also acts in a negative feedback loop to constrain further PI3K mediated signalling
S6 kinase mediated negative feedback mechanisms and leads to enhancement of PI3K
efﬁcacy of mTOR inhibitors alone in the clinic for various cancers. Use of a dual PI3K/mT
PI3K signalling by preventing the phosphorylation of AKT by mTORC2 and by directly ico-inhibition of the function of surrounding cells may be an im-
portant factor in successful treatment.
Ongoing clinical trials with idelalisib are examining the com-
bination with other agents; including rituximab, ofatumumab,
obinutuzumab and bendamustine. Furthermore, a recent publica-
tion showed that combination of idelalisib with ibrutinib is sy-
nergistic, indicating potential beneﬁt from combined or sequential
therapy [11]. In addition to idelalisib, development of other PI3Kδ
inhibitors for the treatment of lymphoid malignancies is ongoing
including TGR-1202, a novel PI3Kδ inhibitor with signiﬁcant dif-
ferences in its chemical structure compared to idelalisib and with
lower reported incidences of colitis in patients. TGR-1202 is cur-
rently in phase I clinical trials, with signiﬁcant nodal responses
observed in 88% of relapsed/refractory CLL patients to date (clin-
icaltrials.gov, NCT01767766).
Duvelisib (IPI-145) targets both PI3Kδ and PI3Kγ isoforms [12]
and induced apoptosis in CLL samples in vitro, abrogated bone
marrow stromal cell-mediated survival, inhibited BCR mediated
signalling and chemotaxis in response to CXCL12 [13]. Importantly,
duvelisib also killed CLL cells that were resistant to ibrutinib [3],
this may hold true with other PI3K inhibitors, and could form an
important strategy for treating patients refractory to ibrutinib.
Duvelisib has completed phase I clinical trials in which 89% of
patients showed a reduction (Z50%) of enlarged lymph nodes and
47% patients showed an overall response to the drug [14]. Duve-
lisib is now in a number of clinical trials for CLL, including in
combination with anti-CD20 antibodies and in patients refractory
to ibrutinib (clinicaltrials.gov, NCT02292225, NCT01871675).
Although these results are extremely promising, the long term
effects of PI3Kδ inhibition in patients are unknown. Will the dis-
ruption of regulatory T cell function over a number of years lead to
increased risk of developing autoimmune disorders? Furthermore,
increased incidences of colitis have been reported in patients
treated with idelalisib, and although the exact cause is unknown,
increased colitis also occurred in a murine model where PI3Kδ
kinase activity was disrupted. Moreover, the PI3Kδ isoform is ex-
pressed by epithelial cells and is known to have a crucial role in
lumen formation [15]. This challenges the concept of restricted
usage of PI3Kδ to haematological cells and therefore raises po-
tential concerns for the effect of PI3Kδ inhibitors on epithelial
tissues; however patient responses to these agents in the short
term may outweigh any potential long term effects.ical agents in pre-clinical/clinical development for CLL indicated. (A) PI3K activation
ns not shown) which in turn initiates downstream signalling events crucial for CLL
approved for CLL treatment are indicted. mTOR exists in two complexes; mTORC1
inding proteins) thereby promoting translation and protein synthesis and mTORC2
downstream of PI3K and mTORC1 and promotes ribosomal translational activity. S6
. Selective inhibition of mTORC1 (for example by everolimus as indicated) abrogates
mediated signalling and AKT activation. This effect is thought to have limited the
OR inhibitor (for example PF-04691502 as indicated) prevents this ampliﬁcation of
nhibiting PI3K.
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hibitors in CLL
PI3Kδ has been the overwhelming target of choice for PI3K
inhibition in CLL; however there is mounting evidence for im-
portant roles of other PI3K isoforms in CLL and of functional re-
dundancy between PI3K isoforms in leucocytes in general [4].
Ampliﬁcation of the PIK3CA locus which encodes for the PI3Kα
catalytic subunit has been identiﬁed in a proportion of CLL pa-
tients [16] and may contribute to constitutive PI3K activation in a
subset of CLL patients. In normal B cells either PI3Kα or PI3Kδ can
mediate tonic BCR signalling and low level AKT phosphorylation,
with PI3Kα able to compensate for the absence of PI3Kδ and
maintain normal B cell development in the bone marrow [4]. In
contrast, agonist-induced AKT phosphorylation is solely PI3Kδ
mediated [4]. Given that BCR derived signalling is crucial for CLL
pathogenesis, the inhibition of both PI3Kα and PI3Kδ may be su-
perior to inhibition of either isoform alone and may overcome any
functional redundancy between isoforms. Interestingly, con-
stitutive PI3Kα activity limited the efﬁcacy of idelalisib in mantle
cell lymphoma and the combined inhibition of both PI3Kα and
PI3Kδ was required to abrogate constitutive AKT phosphorylation
[17].
Pharmacological inhibition of PI3Kα induces apoptosis of CLL
cells in vitro [5,18], and inhibits CLL migration towards CXCL12 [5].
The PI3Kα/δ inhibitor copanlisib induces signiﬁcantly greater
apoptosis of CLL cells compared to idelalisib (IC50 of 450 nM and
410 μM, respectively) in vitro and is currently being assessed in
phase II clinical trials for a number of haematological malignancies
including CLL [19]. In addition, the pan-PI3K inhibitor NVP-
BKM120 showed signiﬁcantly greater cytotoxicity towards CLL
cells than idelalisib (IC50 10 μM vs. 40 μM, respectively) [20], in-
dicating that other PI3K isoforms may, at least in part, compensate
for PI3Kδ inhibition in terms of CLL survival. Results from a phase I
clinical trial using the pan-PI3K inhibitor pilaralisib with 10 CLL
patients showed an acceptable safety proﬁle with lymph node
shrinkage (Z50%) in 60% patients and progression free survival
(Z6 months) in 70% of patients [21]. However, it remains to be
seen whether pan-PI3K inhibition improves clinical response over
PI3Kδ inhibition alone in a larger patient cohort.4. Pan-PI3K/mTOR inhibition as a potential therapeutic option
in CLL
mTOR is crucial for cellular proliferation and is an attractive
therapeutic target; however the use of selective mTOR inhibitors is
hampered by disruption of negative feedback mechanisms via S6
kinase and mTORC2 and subsequent over-activation of PI3K and
AKT, respectively (Fig. 1B). Dual PI3K/mTOR inhibitors may over-
come this effect by directly inhibiting mTOR and preventing over-
activation of AKT via simultaneous inhibition of PI3K. mTOR can
also be activated by MAPK mediated signalling, therefore the in-
hibition of PI3K in combination with inhibition of mTOR may lead
to greater suppression of this pro-survival pathway than PI3K in-
hibition alone. This is demonstrated by a disconnect between
PI3K/AKT activity and phosphorylation of the mTOR target 4E-BP1
in CLL [22], which indicates that inhibition of PI3K alone would not
achieve maximal inhibition of mTOR mediated signalling.
Indeed, CLL cells treated in vitro with the dual PI3K/mTOR in-
hibitor PF-04691502 or idelalisib plus mTOR inhibitor everolimus,
underwent signiﬁcantly greater apoptosis compared to PI3Kδ or
mTOR inhibition alone [23]. PF-04691502 also inhibited chemo-
taxis, reduced BCR stimulated signalling/survival and signiﬁcantly
prolonged survival in a murine model of CLL [23]. Various PI3K/
mTOR inhibitors are progressing through clinical trials for anumber of different cancers and may therefore provide a pro-
mising novel treatment strategy for CLL and other B cell
malignancies.5. Conclusion
The critical importance of PI3K mediated signalling in CLL pa-
thogenesis is demonstrated by the clinical efﬁcacy and recent
approval of the PI3Kδ inhibitor idelalisib. Increased knowledge of
the role other PI3K isoforms have in CLL biology is aiding the
development of PI3K inhibitors with increased cytotoxicity against
CLL cells. A plethora of novel compounds targeting PI3Kδ and/or
multiple PI3K isoforms are now in pre-clinical or clinical studies
and may provide increased therapeutic options for the treatment
of CLL.Contributions
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